According to Coherent Market Insights, the global eosinophilic esophagitis market size is estimated to be valued at USD 237.5 million in 2024 and is expected to surpass USD 1,767.2 million by 2031, growing at a CAGR of 33.2% from 2024 to 2031.
Rising demand for effective treatment
options and increasing disease prevalence drives market growth. Moreover, lack
of effective treatment options and growing awareness about the disease also
contributes to the market growth. Request a Sample Copy of the Report @ https://www.coherentmarketinsights.com/insight/request-sample/4909
According to a report by the American
Partnership for Eosinophilic Disorders (APFED), eosinophilic esophagitis
affects one in every 2,000 individuals in the U.S. It is more prevalent than
Crohn's disease or ulcerative colitis. Market Trends: Focus on new product launches to expand
product portfolio is key trend driving market growth. In June 2022, Allakos
Inc. received the U.S. Food and Drug Administration approval for its late-stage
drug, lirentelimab (AK002). In August 2022, researchers from the Icahn
School of Medicine conducted novel research studying the possibility of using
helminthic therapy. It is an alternative treatment for eosinophilic
esophagitis. Eosinophilic Esophagitis Market Report
Coverage Report
Coverage Details Market
Revenue in 2024 $237.5 million Estimated
Value by 2031 $1,767.2 million Growth
Rate Poised
to grow at a CAGR of 33.2% Historical
Data 2019–2023 Forecast
Period 2024–2031 Forecast
Units Value
(USD Million/Billion) Report
Coverage Revenue
Forecast, Competitive Landscape, Growth Factors, and Trends Segments
Covered By
Drug Class, By Distribution Channel Geographies
Covered North
America, Europe, Asia Pacific, and Rest of World Growth Drivers •
Promising
Results for Potential Drug Candidates •
Increasing
Awareness Programs for Eosinophil-associated disorders Restraints
& Challenges •
Stringent
Regulations for Drug Approval
Market Opportunities: Corticosteroid is expected to dominate the
eosinophilic esophagitis market. It is owing to their anti-inflammatory
properties. Corticosteroids help reduce inflammation and swelling in the
esophagus caused by an allergic reaction. Topical and oral corticosteroids such
as fluticasone and oral budesonide are used as first-line treatment options. Immediate Delivery Available | Buy This
Premium Research Report @ https://www.coherentmarketinsights.com/insight/buy-now/4909
pump inhibitors (PPIs) are also used for
treating eosinophilic esophagitis. PPIs help reduce stomach acid production
which may relieve esophageal inflammation. Key Market Takeaways: The global eosinophilic esophagitis market
is anticipated to witness a CAGR of 33.2% during the forecast period 2024-2031.
This is owing to increasing disease diagnosis rates and the development of
novel targeted drugs. On the basis of drug class, corticosteroids
segment is expected to hold a dominant position. This is due to their
widespread use as first-line therapy options. By distribution channel, hospital
pharmacies segment will remain the major revenue generator owing to higher
patient volumes. North America is expected to hold a
dominant position over the forecast period. This is due to favourable
reimbursement policies in the region. Competitor Insights - Ellodi Pharmaceuticals - EsoCap AG - GlaxoSmithKline plc. - Teva Pharmaceutical Industries Ltd. - Cipla Limited Recent Developments: In February 2024, Takeda Pharmaceutical
Company Limited announced that the U.S. FDA had approved Eohilia for treatment
of eosinophilic esophagitis. This makes Eohilia the first and only approved
oral medication. In January 2024, Regeneron Pharmaceuticals
announced that the U.S. FDA had approved Dupixent for treatment of eosinophilic
esophagitis. It is used in the treatment of pediatric patient aged 1 to 11
years. Find Most Trending Related Reports: Global topical
corticosteroids (steroids) market is estimated to be valued at
US$ 4.12 Bn in 2022, and is expected to exhibit a CAGR of 4.36 % over the
forecast period (2022-2030). Global proton
pump inhibitors market is estimated to be valued at
USD 3.81 Bn in 2024 and is expected to reach USD 5.50 Bn by 2031, exhibiting a
compound annual growth rate (CAGR) of 5.4% from 2024 to 2031. The global omeprazole
market size was valued at US$ 2,668.4 million in 2017, and is expected
to exhibit a CAGR of 5.2% over the forecast period (2018 – 2026).
About Us: Coherent Market Insights is a
global market intelligence and consulting organization that provides syndicated
research reports, customized research reports, and consulting services. We are
known for our actionable insights and authentic reports in various domains
including aerospace and defense, agriculture, food and beverages, automotive,
chemicals and materials, and virtually all domains and an exhaustive list of
sub-domains under the sun. We create value for clients through our highly
reliable and accurate reports. We are also committed in playing a leading role
in offering insights in various sectors post-COVID-19 and continue to deliver
measurable, sustainable results for our clients.
Contact Us: Mr. Shah Phone: US: +1-650-918-5898 UK: +44-020-8133-4027 AUS: +61-2-4786-0457 India: +91-848-285-0837 Email: sales@coherentmarketinsights.com 
Senior Client Partner – Business Development
Coherent Market Insights
